Loading...

VTYX VENTYX BIOSCIENCES INC US FDA Inspections 8-K Filing

VNTY

VTYX

VENTYX BIOSCIENCES INC

(VTYX)

2025 8-K

Show Summary

Show Summary

Clinical Trials

Financial Statements

Investor Update

Q3 Financial Results

Equity Financing

Earnings Reports

Annual Meeting of Stockholders

Preclinical Data Announcement

Appointment of COO

Earnings Reports

Resignation of Officer

Stock Purchase Agreement

Financial Results Announcement

Costs Associated with Exit ...

Financial Results Announcement

Earnings Reports

Financial Results Announcement

Sublease Agreement

Annual Meeting of Stockholders

Earnings Reports

Financial Results Announcement

Investor R&D Day

Management Changes

External Links:

On June 17, 2025, Ventyx Biosciences, Inc. announced promising results from a Phase 2a trial of their Parkinson's drug VTX3232, where all reported side effects were mild and the drug showed efficacy in reducing biomarker levels and improving symptoms

AI Assistant

VENTYX BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.